356 related articles for article (PubMed ID: 17786312)
1. Experimental treatment of ovarian cancers by adenovirus vectors combining receptor targeting and selective expression of tumor necrosis factor.
Murugesan SR; Akiyama M; Einfeld DA; Wickham TJ; King CR
Int J Oncol; 2007 Oct; 31(4):813-22. PubMed ID: 17786312
[TBL] [Abstract][Full Text] [Related]
2. Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene.
Xiong Z; Cheng Z; Zhang X; Patel M; Wu JC; Gambhir SS; Chen X
J Nucl Med; 2006 Jan; 47(1):130-9. PubMed ID: 16391197
[TBL] [Abstract][Full Text] [Related]
3. Fiber-mutant technique can augment gene transduction efficacy and anti-tumor effects against established murine melanoma by cytokine-gene therapy using adenovirus vectors.
Okada Y; Okada N; Nakagawa S; Mizuguchi H; Kanehira M; Nishino N; Takahashi K; Mizuno N; Hayakawa T; Mayumi T
Cancer Lett; 2002 Mar; 177(1):57-63. PubMed ID: 11809531
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase.
Mizuguchi H; Hayakawa T
Cancer Gene Ther; 2002 Mar; 9(3):236-42. PubMed ID: 11896439
[TBL] [Abstract][Full Text] [Related]
5. CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice.
Mizuguchi H; Koizumi N; Hosono T; Ishii-Watabe A; Uchida E; Utoguchi N; Watanabe Y; Hayakawa T
Gene Ther; 2002 Jun; 9(12):769-76. PubMed ID: 12040458
[TBL] [Abstract][Full Text] [Related]
6. Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob.
Koizumi N; Mizuguchi H; Utoguchi N; Watanabe Y; Hayakawa T
J Gene Med; 2003 Apr; 5(4):267-76. PubMed ID: 12692861
[TBL] [Abstract][Full Text] [Related]
7. Fetal muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity adenoviral vectors.
Bilbao R; Reay DP; Hughes T; Biermann V; Volpers C; Goldberg L; Bergelson J; Kochanek S; Clemens PR
Gene Ther; 2003 Oct; 10(21):1821-9. PubMed ID: 12960972
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy.
Wu H; Han T; Lam JT; Leath CA; Dmitriev I; Kashentseva E; Barnes MN; Alvarez RD; Curiel DT
Gene Ther; 2004 May; 11(10):874-8. PubMed ID: 14999229
[TBL] [Abstract][Full Text] [Related]
9. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors.
Liu Q; Zaiss AK; Colarusso P; Patel K; Haljan G; Wickham TJ; Muruve DA
Hum Gene Ther; 2003 May; 14(7):627-43. PubMed ID: 12804145
[TBL] [Abstract][Full Text] [Related]
10. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches.
Vanderkwaak TJ; Wang M; Gómez-Navarro J; Rancourt C; Dmitriev I; Krasnykh V; Barnes M; Siegal GP; Alvarez R; Curiel DT
Gynecol Oncol; 1999 Aug; 74(2):227-34. PubMed ID: 10419736
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer.
Dehari H; Ito Y; Nakamura T; Kobune M; Sasaki K; Yonekura N; Kohama G; Hamada H
Cancer Gene Ther; 2003 Jan; 10(1):75-85. PubMed ID: 12489031
[TBL] [Abstract][Full Text] [Related]
13. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.
Worgall S; Busch A; Rivara M; Bonnyay D; Leopold PL; Merritt R; Hackett NR; Rovelink PW; Bruder JT; Wickham TJ; Kovesdi I; Crystal RG
J Virol; 2004 Mar; 78(5):2572-80. PubMed ID: 14963160
[TBL] [Abstract][Full Text] [Related]
14. Targeting of high-capacity adenoviral vectors.
Biermann V; Volpers C; Hussmann S; Stock A; Kewes H; Schiedner G; Herrmann A; Kochanek S
Hum Gene Ther; 2001 Sep; 12(14):1757-69. PubMed ID: 11560769
[TBL] [Abstract][Full Text] [Related]
15. Enhanced transduction efficiency of fiber-substituted adenovirus vectors by the incorporation of RGD peptides in two distinct regions of the adenovirus serotype 35 fiber knob.
Matsui H; Sakurai F; Katayama K; Kurachi S; Tashiro K; Sugio K; Kawabata K; Mizuguchi H
Virus Res; 2011 Jan; 155(1):48-54. PubMed ID: 20801174
[TBL] [Abstract][Full Text] [Related]
16. An adenoviral vector containing an arg-gly-asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression.
Campbell M; Qu S; Wells S; Sugandha H; Jensen RA
Cancer Gene Ther; 2003 Jul; 10(7):559-70. PubMed ID: 12833136
[TBL] [Abstract][Full Text] [Related]
17. Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy.
Breidenbach M; Rein DT; Wang M; Nettelbeck DM; Hemminki A; Ulasov I; Rivera AR; Everts M; Alvarez RD; Douglas JT; Curiel DT
Hum Gene Ther; 2004 May; 15(5):509-18. PubMed ID: 15144580
[TBL] [Abstract][Full Text] [Related]
18. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.
Chung I; Schwartz PE; Crystal RG; Pizzorno G; Leavitt J; Deisseroth AB
Cancer Gene Ther; 1999; 6(2):99-106. PubMed ID: 10195877
[TBL] [Abstract][Full Text] [Related]
19. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro.
Kelly FJ; Miller CR; Buchsbaum DJ; Gomez-Navarro J; Barnes MN; Alvarez RD; Curiel DT
Clin Cancer Res; 2000 Nov; 6(11):4323-33. PubMed ID: 11106250
[TBL] [Abstract][Full Text] [Related]
20. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma.
Barker SD; Dmitriev IP; Nettelbeck DM; Liu B; Rivera AA; Alvarez RD; Curiel DT; Hemminki A
Gene Ther; 2003 Jul; 10(14):1198-204. PubMed ID: 12833129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
